PubMed Health⌕ Search

Biomedical subjects

E S Ketiladze

Publications and source records attributed to E S Ketiladze.

At least 19 recordsLinked to original sources
PubMed1991

[Chronic hepatitis delta--the course and approaches to therapy].

Variants of chronic hepatitis delta (CHD) course were studied in 94 patients. Slow progress (for decades) occurred most frequently, while rapid progress to hepatic cirrhosis (for 1-2 years) or benign course presenting as greater than 3-year remission were rare findings. In addition to routine therapeutic modalities, except corticosteroids, 43 CHD patients received recombinant alpha 2-interferon (reaferon). Follow-up results evaluated separately for hepatic cirrhosis and free of it CHD patients support clinical promise of Soviet recombinant alpha 2-interferon against CHD.

Adolescent↗
PubMed1990

[Role of delta infection in fulminant course of viral hepatitis].

Sera from 35 fulminant hepatitis patients admitted to the hospital at the USSR AMS Research Institute of Virology in 1985-1989 were studied for specific markers of NB and delta infection. Delta-infection as etiological factor of the disease proved in 26 patients (74.3%). Acute hepatitis of mixed etiology (HBV and HDV) occurred in 17, acute hepatitis delta in 9 patients carrying chronically HBsAg. Acute hepatitis B was verified in the rest 9 patients. Clinical, biochemical and serological aspects typical for the variety of etiological variants of hepatitis running a fulminant course are considered.

Acute Disease↗
PubMed1990

[Reaferon treatment in acute HBsAG-positive viral hepatitis].

Clinical, biochemical and serological examinations of 412 patients with acute HBsAg-positive virus hepatitis were conducted to assess therapeutic efficacy of Soviet recombinant alpha 2-interferon (reaferon). There were 309 cases of acute virus hepatitis B, 103 of delta infection (71--coinfection, 32--superinfection). The study and control groups were assigned randomly. Reaferon i.m. administration started on jaundice day 1-5 and lasted for 10-11 days. The treatment proved effective in acute hepatitis B running a moderately severe and severe course up to the development of acute hepatic encephalopathy. In delta infection reaferon produced response in coinfection only. In fulminant hepatitis the treatment was uneffective.

Acute Disease↗
PubMed1989

[Activation of the interferon system enzymes by recombinant alpha2-interferon in patients with chronic hepatitis B].

Treatment of patients suffering from chronic hepatitis B with recombinant leukocytic interferon (reaferon) increased the levels of circulating interferon and activated interferon-dependent enzymes such as 2-5A-synthetase and histone kinase. Activation of the enzymes was observed for 1 to 2 weeks. After that period it was maintained at the required levels with intramuscular administration of 1-3 million units of reaferon 2 or 3 times a week. In parallel with increasing of the levels of the interferon system enzymes there was observed a decrease in the level of aminotransferase. The reaction of the viral antigens to the treatment with reaferon was not the same: HBe antigen and antibodies to HBe antigen disappeared, the content of HBs antigen and antibodies to delta-interferon did not change.

2',5'-Oligoadenylate Synthetase↗
PubMed1989

[Characteristics of the course and outcome of viral hepatitis A in patients treated at home].

As many as 40 adult patients aged 15 to 40 years with virus hepatitis A treated at home were followed up since October 1987 to March 1988 in 6 districts of Moscow. There were 23 women and 17 men. The control group comprised 101 adult patients (46 women and 51 men) admitted to the Clinical Infectious Hospital No. 1. The diagnosis of virus hepatitis A was made on the basis of the clinico-epidemiologic and biochemical data, supported by detection of specific IgM antibodies to virus hepatitis A. Staying in bed, sparing diet and abundant drinking were indicated to all the patients. The patients who reported for work were followed up for 6 months. The mean duration of disability constituted 34.1 +/- 1.69 days, if the patients were treated at home and 38.6 +/- 1.26 days, provided they received hospital treatment. The number of lingering cases was 4 (10%) during the treatment at home and 11 (10.9%) at hospital treatment. The data obtained attest to the possibility of treating adult patients with virus hepatitis A at home.

Adolescent↗
PubMed1989

[Interferon in the treatment of acute viral hepatitis B].

The Soviet leukocytic alpha 2-interferon obtained by gene engineering was assessed (according to the clinical and biochemical findings) for the therapeutic efficacy in acute viral hepatitis B. The drug was injected intramuscularly to patients with grave and medium-grave hepatitis during 10 days. The treatment was instituted within the first 1-5 days of jaundice. The patients with medium-grave acute viral hepatitis B manifested a beneficial therapeutic effect of alpha 2-interferon obtained by gene engineering as did the patients with the grave disease pattern before they developed the signs of liver encephalopathy.

Acute Disease↗
PubMed1988

[The immune status in variants of the course and outcome of acute delta virus infection].

The immune status was investigated in 32 patients with acute hepatitis of mixed etiology and in 39 HBsAg carriers, superinfected with delta virus. The relationship of changes in the immune status with a course and outcomes of acute delta virus infection was revealed. These changes returned to normal on patients with a cyclic course of disease, persisted in patients with a lingering process, and progressed in the development of subacute liver dystrophy. The most noticeable shifts (a decrease in all indices of the immune system) were revealed in patients with a fulminant course of disease.

Acute Disease↗
PubMed1987

[The outcome of viral hepatitis B and cellular immunity function].

Immunological examination of 158 patients with viral type B hepatitis (VH) was performed over time. Patients with HBsAg elimination for 60 days from the onset of jaundice and a favorable outcome of hepatitis at the height of the process demonstrated a decrease in the relative number of theophylline resistant lymphocytes (T-helpers), a decrease in theophylline sensitive lymphocytes (T-suppressors), an increase in the helper/suppressor (H/S) ratio up to 13.1/1 (the normal ratio being 3.9/1), a certain increase in the number of B-lymphocytes, activation of rosette-forming function of neutrophils, and a tendency to an increase in the activity of natural killer cells (NK). Patients with HBs-antigenemia over 60 days with subsequent convalescence also demonstrated similar changes of immunoregulating T-lymphocyte subpopulations but they developed later in relation to the onset of viral hepatitis. In the formation of chronic persistent hepatitis (CPH) there was no decrease in the absolute and relative number of T-suppressors from the onset of disease, the level of T-helpers and the H/S ratio were moderately lowered. Unlike CPH the suppression of the effector link of the immune system (phagocytosis and NK) and a decrease in the level of T-suppressors were noted in the development of chronic active hepatitis in all the periods of the process. The application of the above regularities to prognosis of VH outcomes, the choice and assessment of efficacy of immunocorrective therapy was discussed.

Adolescent↗
PubMed1987

[Diagnostic significance of detecting respiratory virus antigens in cerebrospinal fluid and brain cells].

Cerebrospinal fluid (CSF) from 202 patients (114 children and 88 adults) was studied by immunofluorescent techniques. Antigens of respiratory viruses in the CSF were most frequently encountered (22%) in patients with the involvement of the central nervous system (usually meningoencephalitis) in the presence of acute respiratory disease. In lethal outcomes in the same group viral antigens in brain cells were also identified. Clinical and morphological findings suggest that these lesions are infectious-allergic in nature. In rare cases (4%) viral antigens in the CSF and brain cells may also be found in patients with acute respiratory diseases without central nervous system involvement which happens when patients' blood-brain barrier is especially permeable.

Adult↗
PubMed1986

[Chronic hepatitis B and delta-infection].

Delta infection was investigated in patients with chronic viral hepatitis by means of detecting antibodies to the delta agent in the patients' blood with the use of radioimmunoassay. It was demonstrated that chronic viral hepatitis B is often (in 44.5% of cases) associated with delta infection and takes a course similar to that of chronic hepatitis A. In this case demonstrable liver injury is observed, which is supported by the clinical, biochemical and morphological findings.

Adult↗